* 0103/DPB1 * 0401 (DP0401) is the most common HLA class II molecule and is present in approximately 45% of the Caucasian population. In this study, soluble HLA-DP0401 molecules were expressed as "empty" class II molecules in insect cells. Utilizing these soluble DP molecules and the Tetramer Guided Epitope Mapping (TGEM) approach, the influenza A Puerto Rico/8/34 matrix protein (MP) derived peptide MP 41−60 VLMEWLKTRPILSPLTKGIL and the Clostridium tetani Tetanus Toxin (TT) derived peptide TT 634−653 DKISDVSTIVPYIGPALNIV were identified as the DP0401 restricted MP and TT epitopes, respectively. In addition, T cells specific for the cancer testis antigen NY-ESO-1 and the breast/ovarian cancer over-expressing antigen Her-2/neu were detected in DP0401 subjects by DP0401 tetramers. The availability of HLA-DP0401 tetramers should facilitate the study of DP restricted T cell responses.
INTRODUCTION
Major histocompatibility complex (MHC) class I tetramer technology (1) was developed 10 years ago as an effective tool to interrogate CD8+ T cell responses. This technology was eventually adapted in the development of MHC class II tetramers for analysis of antigen-specific CD4+ T cell responses. Although a limited number of allele-specific MHC class II tetramers are available, the application of these tetramers has led to a better understanding of CD4+ T responses towards both foreign and self-antigens (2) (3) (4) (5) (6) (7) (8) (9) . Developing additional allele specific class II tetramers will have great scientific merit.
The human histocompatibility leukocyte antigen (HLA) class II region encodes for three sets of class II molecules, HLA-DR, DQ and DP. Each class II molecule is composed of a 33-35 kDa transmembrane α chain and a 26-28 kDa transmembrane β chain, which assemble into a peptide binding receptor (10, 11) . Since the genes encoding HLA-DR, DQ and DP are highly polymorphic, different class II molecules have different peptide binding pockets and bind different sets of peptides (10, 12) . Though there is only one dominant DRA allele, there are 384 DRB alleles (including DRB1 * , DRB3 * , DRB4 * and DRB5 * alleles), 22 DQA1, 42 DQB1, 12 DPA1 and 100 DPB1 polymorphic alleles as recorded in the IMGT/HLA sequence Database (http://www.ebi.ac.uk/imgt/hla) in 2004. These polymorphic alleles can comprise more than 384 HLA-DR, and hundreds of different DQ and DP molecules. Expression of all these HLA class II tetramers would be a technical challenge.
While HLA class II molecules are highly polymorphic, a few alleles in each set of class II molecules are over-represented in the population. The most overrepresented HLA class II molecule is HLA-DP0401 (DPA1 * 0103/DPB1 * 0401) which is present in ∼45% of the Caucasoid population and at least 20% worldwide (13). HLA-DP restricted T cells have been identified in anti-viral (14, 15) and antimicrobial immune responses (16) (17) (18) . HLA-DP mismatches are also linked to acute graft versus host disease and graft rejection after transplantation (19, 20) . Associations of certain DP alleles to autoimmune diseases have also been documented (21) (22) (23) (24) . Importantly, a number of HLA-DP0401 restricted tumor antigen epitopes have been described, e.g., NY-ESO-1, MAGE-A3, and SSX-2 (25) (26) (27) (28) (29) . Production of HLA-DP0401 tetramers will provide important reagent for monitoring antigen-specific DP0401 restricted CD4+ T cell responses in various settings. In this study, we have generated DP0401 antigen-specific tetramers and use TGEM (Tetramer Guided Epitope Mapping) to identify DP0401 restricted T cell responses to influenza A matrix protein (MP) and tetanus toxin (TT) (30) . Using these reagents, DP0401 restricted MP-specific and TT-specific T cell epitopes were identified by TGEM. In addition, T cells specific for the tumor antigens NY-ESO-1 and Her-2/neu were visualized in peripheral blood mononuclear cells (PBMC) of DP0401 subjects.
METHODS

Genes and Constructs for DP0401 Expression
HLA-DP0401 α and β cDNAs were cloned by reverse transcriptase polymerase chain reaction (RT-PCR) from PBMC RNA of a DP0401 subject. The extracellular encoding regions of the two genes were amplified by PCR with 5 and 3 primers containing EcoR I and BamH I sites. Sense and antisense primers for DPA1 * 0103 were 5 -AAA GAA T T C ACC ATG CGC CCT GAA GAC AGA ATG TTC CAT ATC-3 and 5 -AGT GGA T CC GCG CGG AAC CAG GTC TGC TGA CGA CCA GTG CTT GAG GAG CGG CTG GTC-3 , respectively. Sense and antisense primers for DPB1 * 0401 were 5 -AAA ACC GAA T T C ATG ATG GTT CTG CAG GTT TCT GCG GCC-3 and 5 -AGT GGA T CC GCG CGG AAC CAG GTC TGC TGA CGA CTT ACT CCG GGC AGA ATC AGA CTG-3 , respectively. Products from these PCR reactions were inserted in-frame into the pRmHa-3 Drosophila expression vector (gift from Dr. L Goldstein, U of California San Diego, La Jolla, CA) as described before so that the leucine-basic and -acidic dimerization domains were fused at the C-terminus of DP0401 α and β chains, respectively (7) . The sequences of final expression vectors were confirmed by DNA sequencing.
Establishment and Isolation of DP0401 Expressing S2 Cell Line and Clones
Drosophila Schneider 2 (S2) cells were cultured at 26
• C in Schneider's medium with 10% fetal bovine serum (FBS). For transfection, 4 × 10 6 S2 cells were plated into a 6-well plate overnight. A total of 20 µg of vector DNA consisting of HLA-DP0401 α and β chain expression vectors along with neomycin resistant gene expression vector pUChsneo (gift from Dr. M McKeown, Salk Institute, San Diego, CA) at a ratio of 10:10:1, respectively were co-transfected into S2 cells by Calcium Phosphate precipitation method (7) . The cells were selected with 2 mg/mL G418 for 4-6 weeks until a G418 resistant cell line was established. HLA-DP0401 producing clones were isolated by seeding S2 cells at 1 cell/well in 96-well plates with 50% S2 cell conditioned medium and 50% fresh medium in the presence of 2 mg/mL G418. Individual clones were further expanded and induced for expression of HLA-DP0401 with 1 mM CuSO 4 . Five days post-induction, supernatants from induced cell cultures were assayed for production of HLA-DP0401 by immunoblot. Monoclonal antibody (mAb) 2H11 (antileucine zipper mAb, a kind gift from Dr. S Nathenson, Albert Einstein College of Medicine, Bronx, NY) was used for the detection of HLA-DP0401. S2 cell clones that gave strong immunoblot signals were selected for further expansion.
Expression, Purification, and Biotinylation of HLA-DP0401
S2 cell clone that expressed high level of DP0401 was expanded in spinner flasks in 2 L of culture medium. When the cell density reaching 5 × 10 6 cells/mL, expression of HLA-DP0401 was induced with 1 mM CuSO 4 for 5 days. Supernatant was clarified by centrifuging at 10,000 rpm for 10 min, filtered through 0.2 µm filter and loaded onto a 5 mL 2H11 mAb affinity column at 4
• C. The column was washed with 200 mL of PBS containing 0.02% noctyl-β-D-glucopyranoside (OG), followed by 50 mL of phosphate buffer saline (PBS), 0.35 M NaCl, 0.02% OG, and 50 mL of 10 mM Tris-HCl, pH 7.5 and HLA-DP0401 protein was eluted out with 100 mM Tris base, 0.5 M NaCl, pH11.5 and neutralized immediately after elution. Protein containing fractions were pooled and dialyzed into Tris buffer containing 20 mM Tris-HCl, pH 8.0, 10 mM NaCl, 10 mM MgCl 2 . The protein was concentrated to 2 mg/mL and biotinylated with Bir A enzyme in biotinylation buffer (50 mM bicine, pH8.3, 10 mM ATP, 10 mM magnesium acetate, 50 µM biotin, Avidity, Denver, CO) at 26
• C overnight. Excess biotin in the biotinylation reaction was removed by dialysis into peptide loading buffer (0.1 M sodium phosphate, pH 5.9).
SDS-NuPAGE Gel Analysis
10 µg of purified and biotinylated DP0401 monomers were analyzed on 4-12% NuPAGE gradient (Invitrogen, Carlsbad, CA) with 1 × MES SDS running buffer (50 mM 2-(N-morpholino) ethane sulfonic acid (MES), 50 mM Tris base, pH7.2, 0.1% SDS, 1mM EDTA). To determine the in vitro biotinylation efficiency, 10 µg of biotinylated DP0401 monomer were adsorbed with M-280 Streptavidin beads from Dynal Beads, Inc (Brown Deer, WI). After removal of beads, the supernatant was analyzed on NuPAGE gel.
Peptides and Tetramers
A panel of 30 overlapping influenza A MP peptides p1 through p30 (derived from MP of influenza A/Puerto Rico/8/34) were synthesized on polyethylene pins with 9-fluorenylmethoxycarbonyl chemistry by MIMOTOPES (Clayton, Australia). These peptides, each 20-amino acid (aa) in length with a 12-aa overlap between adjacent peptides covered the entire MP protein. Peptides were dissolved in DMSO and peptide pools were generated by mixing five consecutive peptides. A schematic diagram depicting the MP overlapping peptides and strategy of mixing peptide pools is shown in Fig. 1 . There were a total of six MP peptide pools. For the tetanus toxin T cell epitope mapping experiment, one hundred and six 20-aa peptides with 12-aa overlap that spanned the entire tetanus toxin heavy chain were synthesized. The peptides were divided into 21 peptide pools with five consecutive overlapping peptides in each pool with the exception of the last pool which had six peptides. The NY-ESO-1 157−169 peptide, SLLMWITQCFLPV, and Her-2/neu 369−386 peptide, KIFGSLAFLPESFDGDPA, were synthesized with an Applied Biosystems 433A Peptide Synthesizer (Foster City, CA).
Empty biotinylated HLA-DP0401 monomer was loaded with 0.2 mg/mL of either pooled peptides or individual peptides. Loadings were carried out at 37
• C for 72 h in the presence of 2.5 mg/mL (0.25%) n-octyl-β-Dglucopyranoside and 1 mM Pefabloc SC (Sigma-Aldrich, St. Louis, MO). Peptide loaded HLA-DP0401 monomer were tetramerized with phycoerythrin (PE) conjugated streptavidin (Biosource International, Camarillo, CA) at a molar ratio of 8 to 1, respectively. Staining was carried out with 2 × 10 5 cells and 10 µg/mL of tetramers in 100 µl medium at 37
• C for 2 h followed by anti-CD4 staining at 4
• C for 15 min. Cells were analyzed on a FACSCalibur (BD Biosciences, San Jose, CA).
PBMC, Tetramer Guided Epitope Mapping and T Cell Stimulation
PBMC from healthy DP0401 donors with HLA-DPA1 * 0103 and DPB1 * 0401 genotype were used in the MP and TT TGEM experiments (30) as well as the NY-ESO-1 experiments. For the Her-2/neu experiment, PBMC was obtained from a Her-2/neu antibody positive DP0401 breast cancer subject that had been immunized with the Her-2/neu 369−386 peptide vaccine. Vaccines were administered intradermally once monthly for 6 months and sample was obtained after the third vaccination. More detailed composition of the Her-2/neu vaccine and the immunization protocol are described elsewhere (31) . All protocols were approved by the Institutional Review Board and informed consent was obtained from subjects.
The TGEM approach for epitope identification has been described in detail in an earlier report (30) . Briefly, 5 × 10 6 PBMCs per well were plated into 24-well plate and stimulated with 10 µg/mL of pooled peptides in RPMI 1640 with 10% pooled human serum (HS). Each well of cells was stimulated with different pooled peptides (a total of 6 different wells for the MP TGEM experiment and a total of 21 different pools for the TT TGEM experiment). After 7 days, the cells were split into two wells with addition of fresh medium containing 5% of natural human IL-2 (Hemagen, Waltham, MD). The culture was maintained by changing half volume of culture supernatant every 3 days with fresh RPMI 1640 containing 10% HS and IL-2. On day 14, the cultured cells were stained with PE conjugated pooled tetramers and fluorescein isothiocyanate (FITC) conjugated anti-CD4 mAb or peridininchlorophyll-protein (PerCP) conjugated anti-CD4 mAb. Cells that gave positive staining with pooled tetramers were identified and subsequently stained with individual peptide tetramers and anti-CD4 mAb.
For amplification of tumor antigen specific T cells, CD4+ T cells were isolated from PBMCs of DP0401 donors by no-touch CD4+ isolation kit (Miltenyi Biotec, Auburn, CA). CD4+CD25− T cells were obtained from CD4+ T cells by FACS sorting. Two million purified CD4+CD25− T cells were seeded in a 48-well plate wells, which had been plated with adherent cells from the same donor as antigen presenting cells. These T cells were stimulated with tumor antigen peptides or control peptides for 14 days as described (5) and subjected to tetramer staining.
T Cell Cloning
For T cell cloning, tetramer positive T cells were single cell sorted into 96 well round bottom plates using a FACSVantage cell sorter (BD Biosciences, San Jose, CA). These T cells were expanded in the presence of 10 5 irradiated allogeneic PBMCs in 200 µl of RPMI 1640 containing 30% HS and 2 µg/mL of phytohemagglutinin. After 7-10 days culture, the expanded clones were identified and transferred to a flat-bottom 96-well plate. When T cells became confluent, they were transferred into 48 and 24 well plates for further expansion.
RESULTS
Expression of HLA-DP0401 Monomer in Drosophila S2 Cells
Previously, we reported the expression of HLA-DR and DQ molecules in insect cells (7) . In the current study, a similar approach was used to express HLA-DP0401 molecules. S2 cells were transfected with expression vectors carrying genes encoding the extracellular domains of HLA-DP0401 α and β chains. Stable S2 cell clones were established by G418 drug selection followed by limiting dilution cloning. One of the clones was expanded and induced with CuSO 4 for production of soluble HLA-DP0401. Empty HLA-DP0401 molecules were purified from culture supernatant by affinity chromatography using 2H11 mAb. The yield of HLA-DP0401 was about 1.5 mg/L of supernatant. HLA-DP0401 protein was analyzed on SDS-PAGE gel (Fig. 2) . The purified molecule, which carried a biotinylation site at the carboxyl terminus of the DPB1 * 0401 chain, was biotinylated with Bir A enzyme. The biotinylation efficiency was greater than 90% as examined by absorbing 10 µg of biotinylated HLA-DP0401 monomer with Streptavidin beads (Fig. 2, lane 3) .
Identification HLA-DP0401 Restricted MP and TT Reactive T Cells
The TGEM approach was used to identify HLA-DP0401 reactive T cells. PBMCs from a DP0401 healthy subject were stimulated with pools of overlapping synthetic peptides that covered the entire MP of influenza A virus. Fourteen days post-stimulation, PBMCs were stained with PE-labeled DP0401/MP pooled peptide tetramers. As shown in Fig. 3A , a distinct population of tetramer positive cells was identified in the cells stimulated with pool 2 peptides. To further identify the epitope recognized by these CD4+ T cells, PBMCs stimulated with pool 2 peptides were stained with HLA-DP0401 loaded with individual peptides from pool 2. Fig. 3B shows that MP p6 (MP 41−60 VLMEWLKTR-PILSPLTKGIL) is a T cell epitope. HLA-DP0401/MP p6 tetramer positive CD4+ T cells were single-cell sorted on a FACSVantage. These T cells were expanded with irradiated allogeneic feeder cells. Twenty-one out of 53 T cell clones expanded successfully. All T cell clones were stained again and all remained HLA-DP0401/MP p6 tetramer positive (Fig. 3C and data not shown) .
In a similar study, PBMCs from a DP0401 healthy subject were stimulated with 21 pools of overlapping synthetic peptides that covered the 858 aa long tetanus toxin (TT) heavy chain (with each pool having five peptides, with the exception of pool 21 which has six peptides). HLA-DP0401 monomers were also loaded with corresponding TT pooled peptides. Fourteen days post-stimulation, PBMCs were stained with PE-labeled DP0401/TT pooled peptide tetramers. Cells which were stimulated with pool 5 peptides were found to be positive for tetramer binding. The cells were stained again with DP0401 loaded with individual peptides from pool 5. As shown in Fig. 4 , a DP0401-restricted TT epitope, TT 634−653 DKISDVSTIVPYIGPALNIV (TT p23), was also identified.
Identification HLA-DP0401 Restricted Tumor Antigen Specific T Cells
Previous studies have identified a number of tumor antigen epitopes restricted by HLA-DP0401 (25) (26) (27) (28) (29) .
To test whether HLA-DP0401 molecule could be used to identify tumor antigen-specific T cells, HLA-DP0401 monomers were loaded with a known tumor antigenic epitope, NY-ESO-1 157−169 SLLMWITQCFLPV. CD4+CD25− T cells isolated from PBMCs of a health donor carrying HLA-DP0401 allele were stimulated with NY-ESO-1 157−169 or irrelevant peptides. The CD4+CD25− T cell subset was used as previous studies indicated that removal of CD4+CD25+ regulatory T cells facilitate the expansion of autoreactive T cells (5) . After 14 days in vitro stimulation, T cells were stained with HLA-DP0401/NY-ESO-1 tetramers. As shown in Fig. 5A , a low percentage (0.7%) of DP0401/NY-ESO-1 tetramer positive CD4+ T cells were clearly identified. The same tetramer did not stain CD4+CD25− T cells stimulated with an irrelevant peptide (Fig. 5B) indicating the specificity of the T cell responses.
In another set of experiments, PBMC were obtained from a DP0401 breast cancer subject that had been vaccinated with Her-2/neu peptide vaccine in a clinical trial. As the Her-2/neu 369−386 peptide, KIFGSLAFLPESFDGDPA, has a potential DP binding motif (13), we examined the PBMC for the presence of DP0401 restricted Her-2/neu 369−386 responding T cells. Individual peptides, TTp21, TTp22, TTp23, TTp24, and TTp25 that constituted TT pool 5 were individually loaded onto DP0401, these tetramers and anti-CD4-PerCP were then used to stain cells which were stimulated with TT pool 5. DP0401/TTp23 gave positive staining, indicating that TT 176−196 DKISDVSTIVPYIGPALNIV is the DP0401 restricted epitope. CD4+CD25+ depleted CD4+ T cells were stimulated with the Her-2/neu 369−386 peptide, and DP0401/Her-2/neu tetramers were used to assay for the presence of DP0401 restricted Her-2/neu specific CD4+ T cells 14 days post stimulation. Staining with DP0401/Her-2/neu tetramers identified about 2% of low affinity tetramer positive CD4+ T cells, while an irrelevant tetramer DR0401 loaded with collagen II peptide failed to stain these T cells ( Fig. 5C and D) . Collectively, this study indicated that the identification of DP restricted tumor antigen specific T cells with DP tetramers is feasible.
DISCUSSION
This report describes the production of soluble HLA-DP molecules and the uses of DP tetramers in staining DP restricted antigen specific T cells. HLA-DP0401 restricted T cells that were specific for TT, MP, NY-ESO-1, and Her-2/neu epitopes in PBMC were detected by antigen specific DP0401 tetramers.
Though class II tetramer technology has been developed for more than 5 years, the general difficulty in MHC class II tetramers production has limited a broader application. Indeed, protein expression is an experience dependent practice, and different MHC molecules require different methodologies for expression and purification. For example, production of MHC class I tetramers can be achieved by expression of MHC class I molecules in bacteria and functional class I molecules can be refolded in a redox buffer system. A similar approach for production of MHC class II molecules has proven more difficult (10, 32) . On the other hand, HLA-DR0101 (DRA1 * 0101/DRB1 * 0101), DR0401 (DRA1 * 0101/ DRB1 * 0401) and DR1501 (DRA1 * 0101/DRB1 * 1501) and HLA-DQ6 (DQA1 * 0301/DQB1 * 0602) can be expressed at high levels in insect cells, while DQ8 (DQA1 * 0301/DQB1 * 0302) is poorly expressed. The reason for these differences remains elusive. In this current study, we demonstrated that HLA-DP0401 molecules could be expressed at high levels in insect cells. The biochemical properties of HLA-DP0401 are similar to the HLA-DR molecules, in that they can be efficiently loaded with peptides at mild acidic pH (pH5.9). The empty HLA-DP0401 molecule is relatively stable and can be kept at 4
• C for at least 6 months without loss of biological function as evaluated by generating antigen specific tetramers for staining T cells.
HLA-DP0401 class II tetramer is of particular interest as HLA-DP0401 is the most prevalent allele among all HLA class II alleles. It is estimated that up to 45% of the Caucasian population has the DP0401 allele (13). Such a wide distribution of this specific allele provides the opportunity to use HLA-DP0401-restricted antigenic epitopes as peptide-based vaccines for the general population. In this study, we used the TGEM approach to identify DP0401 restricted MP and TT antigenic epitopes. The magnitude of the DP restricted MP responses was much weaker compared to the DR restricted MP responses as reported earlier (9) . DP restricted T cells directed against tumor antigens have been identified (25) (26) (27) (28) (29) . In this study, we demonstrated that that DP0401 restricted NY-ESO-1 T cells was detected in a healthy subject by DP tetramers. In an earlier report, we described the detection of DR restricted NY-ESO-1 T cells in healthy subjects by DR tetramers. The DP restricted NY-ESO-1 response was also weaker compared to the DR restricted NY-ESO-1 responses as reported (5) . The weaker DP restricted MP and NY-ESO-1 responses may be related to low level of DP expression on antigen presentating cell surfaces. DP0401/Her-2/neu specific tetramers were used to detect Her-2/neu specific T cells. The magnitude of the Her-2/neu specific responses was stronger compared to the MP or NY-ESO-1 responses. The stronger Her-2/neu specific responses may be due to the repeated vaccination of the Her-2/neu peptide in the subject being studied. The results also suggest the possibility of using DP0401 tetramers to quantify the precursor frequency of tumor immune responsive T cells in patients (5) . More importantly, new HLA DP0401 restricted tumor antigen epitopes can be mapped by applying the TGEM technique. Identification of novel CD4+ T cell epitopes toward tumor antigens may lead to advances in vaccine design and immune monitoring.
